March 7, 2018 · Cancer, Cancer Research · (No comments)

Lots of people who eventually find out that they have cancer are surprised as they were oblivious to the known signs and basic symptoms. CTCA and WebMD are now confronting the widespread ignorance of cancer that is a huge problem in the world today. When someone doesn’t know something crucial regarding their health, they could end up suffering much more than they needed to. Cancer Treatment Centers of America have always been willing to share any of their cancer knowledge both to other medical professionals and cancer care providers and to the many individuals that have turned to them for help.

CTCA hopes to educate everyone on various cancer information. Their biggest goal is to cut down and hopefully someday stop death from occurring just because someone didn’t know how serious their symptoms were. By giving out more cancer details over the Internet, CTCA is targeting a new people group. WebMD is often the site that many familiar with the Internet individuals turn to with health related questions. These Internet browsers have come to trust this healthcare site to give highly researched information. Other Internet sites don’t follow these stricter guidelines before they print an article. CTCA and WebMD combined their resources to bring new cancer healthcare information for online users to easily read. Often, patients that come to Cancer Treatment Centers of America will complain that they didn’t really understand what their healthcare providers were telling them. Sometimes cancer and other healthcare related information is spoken as healthcare providers are used to hearing it.

The problem with this format is that everyday individuals not familiar with healthcare lingo often cannot receive the understanding of spoken information. This is a huge reason whey CTCA have recently joined together with WebMD so the highly complex and confusing medical jargon could be broken down into everyday language that most anyone can understand. Cancer Treatment Centers of America has been in the cancer care business for decades. Their full commitment to all of their patients is very evident in the way that care is done at the five CTCA facilities. Many are relieved when they realize how caring and compassionate the healthcare providers and many supportive staff are to each of their patients. The holistic care approach coined by CTCA is able to treat the entire person rather than just the cancer. This impresses patients greatly, and the methodology does seem to work.

December 15, 2017 · Cancer, Cancer Research · (No comments)

The cancer menace affects a lot of people across the world. The disease has caused pain and affliction to lot families across the globe. In America alone, at least 40 percent of adults are diagnosed with cancer at some point in their lives. National Cancer Institute revealed that close to 15 million people in the U.S. were diagnosed with cancer in 2014. The figures are expected to shoot to close to 20 million in the coming ten years. These figures can, however, come down if there is adequate information on specific treatment options for cancer in our hospitals. Lack of adequate information is one of the hindrances to the treatment of cancer.

Cancer Centers of America are one of the organizations that have put a spirited fight against cancer. The organization, through their affiliate hospitals, has teamed up with Nanthealth and Allscripts to roll out a new program that will enable quick access to critical information needed during the cancer treatment process.The new platform created by the three organizations will allow clinicians and researchers to access a pool of cancer care data. The database will continuously be updated by oncologists and physicians who have experience and expertise in dealing with different types of cancer. The critical information in the database can be accessed within a few clicks.

The three organizations launched the partnership in 2016 as they tried to brainstorm on how they can deliver better services to the cancer patients. The new platform is known as clinical pathways, and it will allow the eviti system by Nanthealth to access the Allscripts Sunrise EHR.The Allscripts Sunrise EHR contains more than 2700 evidence-based treatments which allow clinicians and oncologists to weigh on different treatment possibilities that they can recommend to their patients. The integrity of the clinical pathways program is assured since it is maintained by highly experienced oncologists and researchers in America.Through the clinical pathways platform, oncologists can create customized treatment plans with the input from the patients. The platform also helps them to compare treatment options and costs, and also examine other complimentary services that a cancer patient would consider.

November 23, 2016 · Cancer Research · (No comments)

In 1997 Clay Siegall co-founded Seattle Genetics Company on a foundation of drug development, scientific innovation, and rigorous research in addition to the passion of serving patients. Mr. Clay is the chairman of the Board, the CEO and the company’s president. Seattle Genetic Company develops a diverse group of preclinical and clinical product candidates with the aim of cancer varieties and autoimmune indications. Through Siegall’s leadership, he has guided the company to its recent position of Antibody Drug Conjugate (ADC) development as well as securing the FDA (2011) approval of its first ADC products.

Under collaboration with Genentech, MedImmune, CuraGen and Takeda Pharmaceutical companies, ADCETRIS is currently a global product approved in more than 60 countries. Noteworthy to mention, Dr. Clay has guided Seattle Genetic Company to capital-raising activities attaining $1.2 billion from private and public funding. Moreover, the company has gone through premeditated licenses such as AbbVie and Pfizer for the ADC technologies which have resulted to more than $325 million. Clay Siegel is an excellent example of hardworking man from his overall achievements since there are few genetic companies worldwide that can be contrasted with his work.

In social media perspective, the gentleman has created immersive awareness about cancer and the research in place. To begin with, his Facebook page well known of valuable information of conferences discussions, resolution, and new ideas. Furthermore, Clay Siegall website is available in the essence of the company and development of the research. Additionally, he considers rapid technology development hence medicine elements should develop with it.
In conclusion, since 1997 Dr. Clay has done extremely recommendable work from Seattle Genetic company launch to its current position. Moreover, a lot of people are in hope for better things to in future from the rise of medicine technology. Finally, the genetic industry is currently competitive than ever though a lot of people are looking up to work with Clay Siegall in this industry as from his experience.

September 24, 2016 · Cancer Research · (No comments)

Seattle Genetics is an innovative biotechnological company that is focused on discovering new cancer treatments. CEO Clay Siegall built the company to assist his patients through drug developments, medical research, and new scientific discoveries. Seattle Genetics has generated more than $300 million under Dr. Siegall’s leadership by entering multiple licenses with big pharmaceutical companies such as Pfizer, GlaxoSmithKline, Roche, and Abbvie. He has raised more than $675 million in revenues for his biotechnological company through public and private offerings to continue working on antibody-drug conjugates (ADCs)to cure cancer.

Through reliable scientific inquiry, integrity, and revolutional therapies, Seattle Genetics has built a strong and honest corporate culture. Clay Seagall has structured his company to collaborate on new CDCs through teamwork. Dr. Siegall also organized a positive work environment where new contributions from staff members are encouraged. Mutual respect at the company has led to Seattle Genetics employees focusing on ways to improve health together through a shared dedication.

ADCs are important to Seattle Genetics because they can spare healthy cells which greatly reduces the harmful effects of typical chemotherapy treatments. As a result, anti-tumor antibodies can directly attack cancer cells while sparing healthy cells. The biotechnological company does not just offer one type of drug to treat cancer, but a whole family of treatments meant to target different types of cancer cells. There are 20 different types of ADCs being researched that show promise for helping cancer patients live and feel better. ADCETRIS is one type of ADC that is being evaluated as a potential treatment for lymphomas. SGN-CD322 is also being evaluated as a possible treatment for the advanced stages of Leukemia.

Seattle Genetics is a leader in cancer treatment research. The innovative approach led by Clay Seagall has helped the company earn a reputation for being both innovative and compassionate.